FENNEC PHARMACEUTICALS INC (FENC)
Health Care · specialty pharmaceuticals · NASDAQ
Fennec Pharmaceuticals is a commercial-stage biopharmaceutical company providing the first and only FDA-approved therapy to prevent permanent hearing loss caused by cisplatin chemotherapy in pediatric cancer patients.
What FENNEC PHARMACEUTICALS INC does
Fennec Pharmaceuticals is a commercial-stage specialty pharmaceutical company focused on the prevention of cisplatin-induced ototoxicity (CIO). Its primary product, PEDMARK (sodium thiosulfate injection), is the only FDA and European Commission-approved therapy for reducing the risk of chemotherapy-induced hearing loss in pediatric patients with non-metastatic solid tumors. The company markets PEDMARK directly in the U.S. and utilizes an exclusive licensing agreement with Norgine to commercialize the product in Europe, Australia, and New Zealand.
Recent developments
On March 16, 2026, the company settled patent litigation with Cipla regarding PEDMARK, ensuring no generic entry in the U.S. until September 2033. The company is actively expanding real-world clinical data to evaluate the potential use of PEDMARK in adult patients, including those with head and neck cancers and testicular germ cell tumors.
From FENNEC PHARMACEUTICALS INC's filing of 2026-08-13.
Themes: oncology / cancer supportive care, pediatric medicine, orphan drugs, cisplatin-induced ototoxicity prevention
Fundamentals
- Price$10.63 as of 2026-10-08 close
- Market cap$373M as of 2026-08-11 (share count; price 2026-10-08)
- 1-year return+15.3% 2025-10-08 close $9.22 → 2026-10-08 close $10.63
- P/En/a negative earnings
- Net margin-21.8% FY2025, SEC XBRL
- Gross margin+94.1% FY2023, SEC XBRL
- ROE-27.5% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-03
- Revenue growth (YoY)+33.8% as of 2026-09-03
- Revenue CAGR (3y)+207.5% SEC XBRL
- Beta1.03 as of 2026-09-03
- Last reported earnings2026-03-24 most recent in our data — SEC EDGAR Form 8-K (Item 2.02); no newer announcement filed
How FENC compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- gross margintop 10% 189 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How FENNEC PHARMACEUTICALS INC looks technically
FENNEC PHARMACEUTICALS INC (FENC) is trading 18.4% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 75 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 47, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 5 trading days ago. It is 19.8% below its highest point of the past year. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move. Trading volume is unusually light — only about 36% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 18.4% above its 200-day average, the long-term trend line — a longer-term uptrend | +18.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $11.18 | $11.18 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $8.98 | $8.98 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 16 calendar days ago — the swings before that are what the structure reading is measured on | 16 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 11.31. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 75 trading days ago — a "golden cross", a bullish long-term signal | 75 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 27, with sellers in control | 26.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 47, neither overbought (above 70) nor oversold (below 30) | 46.8 |
|---|---|---|
| Position in its 14-day range | it is trading around the middle of its 14-day range ($10.01 to $11.31) — its "stochastic" reading is 48 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 47.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 22 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $13.25 | $13.25 |
|---|---|---|
| From the 52-week high | it is 19.8% below its 52-week high (its highest price of the past year) | -19.8% |
| Above the 52-week low | it is 88.1% above its 52-week low (its lowest price of the past year) | +88.1% |
| Below the 52-week high | it is 19.8% below its highest point of the past year | 19.8% |
| Since a 20-day breakout | it made a new 20-day low about 5 trading days ago | 5 sessions |
| Since a 55-day breakout | it made a new 55-day high about 42 trading days ago | 42 sessions |
| All-time high | its highest closing price on record is $14.99 (set on 2018-04-09) | $14.99 |
| Given back of the 52-week move | over the past year its closes ranged ($5.77 to $12.78), and it has given back roughly a third of its rise from last year’s low — 31% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $8.22 to $8.45. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 30.7% |
| From the all-time high | it is 29.1% below its all-time high | -29.1% |
| Nearest price level | it is trading 5.1% above a support level at $10.09 — a price it turned at twice since 2026-07-08, most recently on 2026-09-15. Since 2024-10-08 it has 16 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -5.1% |
| All-time low | its lowest closing price on record is $0.287 (set on 2015-11-27) | $0.287 |
| Above the all-time low | it is 3603.8% above its all-time low | +3,604% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move | 0th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.5396 between its high and its low — about 5.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.5396 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $10.21 and $11.07 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $10.21 – $10.64 – $11.07 |
| Typical daily range (% of price) | its price moves about 5.1% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.1% |
| Stretch from the 200-day average | it is trading 3.1 daily ranges above its 200-day average price (18.4% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.1 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 36% of its 30-day average | 0.36× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-10-08 0.9% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.9% |
|---|---|---|
| Gap filled | a 2.2% gap up opened on 2026-08-17 has been "filled" 37 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 37 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +2.71% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 15.7 percentage points (the stock lost 14.6% while the market gained 1.0%) | -15.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 0.1 percentage points (the stock gained 3.7% while the market gained 3.8%) | -0.1% |
| vs market, 6 months | over the past 6 months this stock beat the market by 48.1 percentage points (the stock gained 65.6% while the market gained 17.5%) | +48.1% |
| vs market, 12 months | over the past 12 months this stock beat the market by 0.3 percentage points (the stock gained 15.3% while the market gained 15.0%) | +0.3% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: MACD momentum is negative, a strong downtrend, with sellers in control, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 3.8% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 4.7% of the share price. | -3.8% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 13% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $9.37 — a volume-weighted average of daily closes over 188 sessions, not a true tick-by-tick VWAP. | +13.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 8% below the average price paid since it last reported on 2026-08-13 (its 10-Q), so the typical buyer over that stretch is under water. That average is $11.50 — a volume-weighted average of daily closes over 40 sessions, not a true tick-by-tick VWAP. | -7.6% |
Price levels it has turned at before
FENC last closed at $10.63 on 2026-10-08. Since 2024-10-08 it has turned at 16 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $10.09 | Support | 5.1% below the last close | turned there twice · 2026-07-08 to 2026-09-15 |
| $11.29 | Resistance | 6.2% above the last close | turned there three times · 2026-06-29 to 2026-09-22 |
| $9.85 | Support | 7.4% below the last close | turned there twice · 2025-10-06 to 2026-07-21 |
| $9.41 | Support | 11.5% below the last close | turned there twice · 2025-08-13 to 2026-07-31 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $11.31.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 8 trading days, since 2026-09-29.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · in a Bollinger Band volatility squeeze · beating the market · Under water since its last earnings report (below the anchored VWAP) · Trading below the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · bollinger bands · volume and relative volume
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.33 mean, 1=Strong Buy…5=Strong Sell) — 6 analysts
- Mean price target$17.67 range $16.00 – $20.00; median $18.00
Analyst estimates, as of 2026-10-08. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for FENC
- Consensus EPS estimate$0.106 next reporting period, as of 2026-10-08
- Estimate change, 30 days+$0.084 from $0.022, on 2026-09-03, 35-day window
- Readings revised upward14% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["High dependence on a single commercial product, PEDMARK, for revenue and growth.","Risks associated with ongoing intellectual property and patent protection, including potential for future generic competition.","History of operating losses and the necessity for potential additional financing to support long-term commercialization and development."]
What changed in the latest 10-Q
AI-assisted comparison of FENC's 10-Q filed 2026-08-13 against the prior one filed 2026-05-14.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-13) states that during 2025, Norgine made PEDMARQSI commercially available in the U.K. and Germany.
- Newer filing (2026-08-13) splits the patent discussion into a new paragraph beginning 'In September 2022' and includes text ending with 'and Russ' (appears truncated).
- Removed:
- Older filing (2026-05-14) states that during 2025, Norgine made PEDMARQSI commercially available without specifying the U.K. and Germany.
- Reworded:
- Newer filing (2026-08-13) changes 'the Company's plans and strategy for its business' to 'our plans and strategy for our business' in the forward-looking statements caution.
- Newer filing (2026-08-13) splits the patent discussion into a new paragraph, whereas the older filing (2026-05-14) presented that discussion within the same paragraph following the Orphan Drug Exclusivity sentence.
- Notes:
- The newer filing text appears truncated at 'and Russ' in the patent discussion, limiting full comparison of that portion.
- The older filing text also appears truncated at 'and patent applications covering a' in the final sentence.
Risk Factors
- Added:
- Newer filing (2026-08-13) discloses that Robert Andrade, the Company's Chief Financial Officer, adopted a Rule 10b5-1 trading arrangement on May 22, 2026 covering disposition of up to 75,000 shares, terminating on September 30, 2026 unless earlier terminated.
- Newer filing (2026-08-13) discloses that Marco Brughera, a current member of the Company's Board of Directors, adopted a Rule 10b5-1 trading arrangement on June 16, 2026 covering disposition of up to 55,545 shares, terminating on June 25, 2027 unless earlier terminated.
- Reworded:
- Newer filing (2026-08-13) states 'During the quarter ended June 30, 2026, no other director or officer of the Company adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement", as each term is defined in Item 408(a) of Regulations S-K.' Older filing (2026-05-14) stated 'During the quarter ended March 31, 2026, no director or officer of the Company adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulations S-K.'
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 5 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-040 buys · 1 sell ($159958) — 1 selling insider
- Last 90 days · read to 2026-10-040 buys · 5 sells ($1M) — 4 selling insiders
- Last 180 days · read to 2026-10-040 buys · 9 sells ($2M) — 5 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-15. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about FENC's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding FENC as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 2,435,130
- Reported value $26,177,652
reported quarterly holdings change (2026-03-31 → 2026-06-30): 1 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about FENC's institutional holders → See what each manager we track holds →
Short interest (FINRA)
FENC had 545,039 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
FENC had 1.55% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 2.11 days to cover at the same settlement.
- Reported short interest (shares) 545,039
- Short interest (% of shares outstanding) 1.55%
- Prior settlement (shares) 520,659
- Reported change 4.68%
- Days to cover (reported) 2.11
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- generic pharmaceutical manufacturers (e.g., Cipla)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
FENNEC PHARMACEUTICALS INC is found in…
FENC ranks in…
Frequently asked questions
What does FENNEC PHARMACEUTICALS INC (FENC) do?
Fennec Pharmaceuticals is a commercial-stage specialty pharmaceutical company focused on the prevention of cisplatin-induced ototoxicity (CIO). Its primary product, PEDMARK (sodium thiosulfate injection), is the only FDA and European Commission-approved therapy for reducing the risk of chemotherapy-induced hearing loss in pediatric patients with non-metastatic solid tumors. The company markets PEDMARK directly in the U.S.
What sector is FENNEC PHARMACEUTICALS INC (FENC) in?
FENNEC PHARMACEUTICALS INC (FENC) is classified in the Health Care sector. Its industry is specialty pharmaceuticals. It trades on NASDAQ.
Who are FENNEC PHARMACEUTICALS INC's (FENC) competitors?
Notable peers of FENNEC PHARMACEUTICALS INC (FENC) include generic pharmaceutical manufacturers (e.g., Cipla). This peer set is informational only — not financial advice.
Is FENNEC PHARMACEUTICALS INC (FENC) overbought or oversold right now?
FENNEC PHARMACEUTICALS INC (FENC) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 47, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on FENC come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.